FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF - GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD

Title:

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2017/012559

Kind Code:

A1

Abstract:

Disclosed are a fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janus kinase, FGFR kinase, FLT3 kinase and Src family kinase.

More Like This:

WO/2012/156377	STEPWISE ASSEMBLED CAPTURE COMPOUNDS AND METHOD FOR ISOLATING PROTEINS FROM COMPLEX MIXTURES
WO/2020/159249	COMPOSITION, ORGANIC OPTOELECTRONIC ELEMENT, AND DISPLAY DEVICE
WO1999011624	OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY

Inventors:

XU ZUSHENG (CN)
ZHANG NONG (CN)
WANG TINGHAN (CN)
SUN QINGRUI (CN)
WANG YUGUANG (CN)

Application Number:

PCT/CN2016/090798

Publication Date:

January 26, 2017

Filing Date:

July 21, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD (CN)

International Classes:

C07D495/04; A61K31/519; A61P9/10; A61P35/00; A61P35/02; A61P37/06; C07D401/14; C07D405/14; C07D471/04

Domestic Patent References:

WO2011049332A2	2011-04-28
WO2015027222A2	2015-02-26
WO2009062258A1	2009-05-22
WO2011079231A1	2011-06-30
WO2014023385A1	2014-02-13
WO2014037750A1	2014-03-13

Other References: